Ian McDonald
Chief Executive Officer, Director
New approaches to neuroscience create Bright Minds
Our Approach
Healing the central nervous system & brain through the regulation of serotonin
Based on a proprietary chemistry platform Bright Minds have developed highly selective 5-HT2A and 5-HT2C agonists without 5-HT2B activity.
Pipeline
Our Science
Our team of neuroscientists, drug developers and physicians are tackling the big problems in mental health and neurology
Our Team
The A team in brain health innovation
Jan Torleif Pedersen
Director, Chief Science Officer
Mark A. Smith
Chief Medical Officer
Ryan Cheung
Chief Financial Officer
Jianmin Duan Ph.D
Vice President of Pharmacology
Dr. John McCorvy Ph.D
Senior Advisor
John McCall, Ph.D
Senior Advisor
Krista Lanctot PhD
Advisor
Lew Truex
Toxicology Advisor
Dr. Narayan R. Kissoon MD
Senior Advisor
Dr. Peter R. Kowey, MD
Advisor
Dr. Guilio Vistoli Ph.D
Senior Advisor
Alex Vasilkevich
Chief Operating Officer, VP Corporate Development
